Zydus Lifesciences

ZYDUSLIFE.NSApproved

Ahmedabad, IndiaFounded 1952zyduslife.com

Zydus Lifesciences Limited, formerly Cadila Healthcare, is a leading Indian multinational pharmaceutical company founded in 1952. The company operates across the entire pharmaceutical value chain with a strong presence in generic drugs, biosimilars, and consumer healthcare products. With manufacturing facilities in India and the US, Zydus serves markets globally including the United States, Europe, and emerging markets, maintaining a robust pipeline of over 300 molecules under development.

Market Cap

$9.6B

Founded

1952

Employees

25,000+

Focus

Biotech

ZYDUSLIFE.NS · Stock Price

USD 890.15+548.05 (+160.20%)

Historical price data

AI Company Overview

Technology Platform

Integrated pharmaceutical platform spanning generic drugs, biosimilars, vaccines, and novel drug delivery systems with strong API manufacturing capabilities.

Pipeline Snapshot

23 drugs in pipeline, 6 in Phase 3

Drug	Indication	Stage
Saroglitazar	NAFLD	Approved
Desidustat	Chronic Kidney Diseases	Approved
Desidustat Oral Tablet + Darbepoetin Alfa	Chronic Kidney Disease Stage 3	Phase 3
Desidustat Oral Tablet + Epoetin Alfa	Chronic Kidney Disease Stage 5 on Dialysis	Phase 3
Measles-Rubella vaccine (Live) I.P. (Freeze Dried) of M/s. Zydus Lifesciences Lt...	Measles	Phase 3

Funding History

IPOUndisclosedUndisclosedJun 15, 2000

FDA Approved Drugs

257

DAPSONEANDAFeb 26, 2026

IVERMECTINANDAFeb 26, 2026

BOSENTANANDAFeb 17, 2026

Opportunities

Significant growth potential through expansion in US generics market, biosimilar launches in developed markets, and leveraging India's growing healthcare demand.

The company's diverse pipeline and manufacturing capabilities position it well for strategic partnerships and acquisitions.

Risk Factors

Key challenges include intense competition in generic markets, regulatory compliance costs, currency volatility, and potential patent litigation.

The company must also navigate evolving pricing pressures in key markets and maintain quality standards across global operations.

Competitive Landscape

Competes with major Indian pharma companies like Sun Pharma, Dr. Reddy's, and Cipla domestically, while facing global competition from Teva, Sandoz, and other generic manufacturers. Differentiated through integrated manufacturing, diverse portfolio, and strong R&D capabilities.

Publications

Patents

Pipeline

FDA Approvals

257